Dabigatranum Etexilatum
39 medicamente autorizate în România conțin substanța activă Dabigatranum Etexilatum.
Ce este Dabigatranum Etexilatum?
Dabigatranum Etexilatum este o substanță activă (DCI - Denumire Comună Internațională) din clasa terapeutică Dabigatran Etexilate (cod ATC B01AE07). Acțiunea terapeutică principală: Agenti Antitrombotici Inhibitori Directi ai Trombinei. În nomenclatorul ANM România sunt autorizate 39 produse medicamentoase care conțin Dabigatranum Etexilatum ca substanță activă.
Formele farmaceutice disponibile: caps., granule drajefiate, pulb. + solv. pt. sol. orala.
Informațiile de pe această pagină provin din nomenclatorul oficial ANM. Consultați medicul sau farmacistul pentru recomandări personalizate.
Proprietăți chimice
Sursă: PubChem (NIH) · CID 216210
- Formula moleculară
- C25H25N7O3
- Greutate moleculară
- 471.5000 g/mol
- Număr CAS
- 211914-51-1
- InChIKey
- YBSJFWOBGCMAKL-UHFFFAOYSA-N
- Denumire IUPAC
- 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
- Alte denumiri
- Dabigatran, BIBR-953, Pradaxa (dabigatran), BIBR 953 ZW, I0VM4M70GC, BIBR-953-ZW, CHEBI:70752, DTXSID50175419
| Denumire comercială | Concentrație | Formă farmaceutică | Producător | Cod ATC | Prospect |
|---|---|---|---|---|---|
| DABIGATRAN ETEXILAT DR. REDDY'S 110 mg | 110mg | Caps. | Betapharm Arzneimittel Gmbh - Germania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT DR. REDDY'S 150 mg | 150mg | Caps. | Betapharm Arzneimittel Gmbh - Germania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT DR. REDDY'S 75 mg | 75mg | Caps. | Betapharm Arzneimittel Gmbh - Germania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LABORATORIOS LICONSA 110 mg | 110mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LABORATORIOS LICONSA 150 mg | 150mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LABORATORIOS LICONSA 75 mg | 75mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LICONSA 110 mg | 110mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LICONSA 150 mg | 150mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT LICONSA 75 mg | 75mg | Caps. | Laboratorios Liconsa, S.a. - Spania | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT VIATRIS 110 mg | 110mg | Caps. | Mylan Hungary Kft. - Ungaria | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT VIATRIS 150 mg | 150mg | Caps. | Mylan Hungary Kft. - Ungaria | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILAT VIATRIS 75 mg | 75mg | Caps. | Mylan Hungary Kft. - Ungaria | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILATE ACCORD 110 mg | 110mg | Caps. | Accord Healthcare Polska Sp. Z O.o. - Polonia | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILATE ACCORD 150 mg | 150mg | Caps. | Accord Healthcare Polska Sp. Z O.o. - Polonia | B01AE07 | 📄 Prospect |
| DABIGATRAN ETEXILATE ACCORD 75 mg | 75mg | Caps. | Accord Healthcare Polska Sp. Z O.o. - Polonia | B01AE07 | 📄 Prospect |
| DAROXOMB 110 mg | 110mg | Caps. | Galenicum Health, S.l.u. - Spania | B01AE07 | 📄 Prospect |
| DAROXOMB 150 mg | 150mg | Caps. | Galenicum Health, S.l.u. - Spania | B01AE07 | 📄 Prospect |
| DAROXOMB 75 mg | 75mg | Caps. | Galenicum Health, S.l.u. - Spania | B01AE07 | 📄 Prospect |
| DAXANLO 110 mg | 110mg | Caps. | Krka, D.d., Novo Mesto - Slovenia | B01AE07 | 📄 Prospect |
| DAXANLO 150 mg | 150mg | Caps. | Krka, D.d., Novo Mesto - Slovenia | B01AE07 | 📄 Prospect |
| DAXANLO 75 mg | 75mg | Caps. | Krka, D.d., Novo Mesto - Slovenia | B01AE07 | 📄 Prospect |
| GRIBERO 110 mg | 110mg | Caps. | Pharmadox Healthcare Ltd. - Malta | B01AE07 | 📄 Prospect |
| GRIBERO 150 mg | 150mg | Caps. | Pharmadox Healthcare Ltd. - Malta | B01AE07 | 📄 Prospect |
| GRIBERO 75 mg | 75mg | Caps. | Pharmadox Healthcare Ltd. - Malta | B01AE07 | 📄 Prospect |
| PRADAXA 110 mg | 110mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 110mg | 110mg | Caps. | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 150 mg | 150mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 150mg | 150mg | Caps. | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 20 mg | 20mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 30 mg | 30mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 40 mg | 40mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 50 mg | 50mg | Granule Drajefiate | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 6,25 mg/ml | 6,25mg/ml | Pulb. + Solv. Pt. Sol. Orala | Catalent Germany Schorndorf Gmbh - Germania | B01AE07 | 📄 Prospect |
| PRADAXA 75mg | 75mg | Caps. | Boehringer Ingelheim Pharma Gmbh & Co. kg - Germania | B01AE07 | 📄 Prospect |
| TELEXER 110 mg | 110mg | Caps. | Gedeon Richter Polska Sp. Z O.o. - Polonia | B01AE07 | 📄 Prospect |
| TELEXER 150 mg | 150mg | Caps. | Gedeon Richter Polska Sp. Z O.o. - Polonia | B01AE07 | 📄 Prospect |
| WASEDOC 110 mg | 110mg | Caps. | Towa Pharmaceutical Europe S.l. - Spania | B01AE07 | 📄 Prospect |
| WASEDOC 150 mg | 150mg | Caps. | Towa Pharmaceutical Europe S.l. - Spania | B01AE07 | 📄 Prospect |
| WASEDOC 75 mg | 75mg | Caps. | Towa Pharmaceutical Europe S.l. - Spania | B01AE07 | 📄 Prospect |